112677-67-5

Basic information

• Product Name: 3-IMIDAZOL-1-YL-PHENYLAMINE
• Synonyms: 3-IMIDAZOL-1-YL-PHENYLAMINE;3-(1H-imidazol-1-yl)benzenamine;BenzenaMine, 3-(1H-iMidazol-1-yl)-;3-imidazol-1-ylaniline
• CAS NO: 112677-67-5
• Molecular Formula: C₉H₉N₃
• Molecular Weight: 159.191
• Mol File: 112677-67-5.mol

Chemical Properties

• Melting Point: 112-114 °C
• Boiling Point: 373.1±25.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 5.53±0.10(Predicted)
• CAS DataBase Reference: 3-IMIDAZOL-1-YL-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-IMIDAZOL-1-YL-PHENYLAMINE(112677-67-5)
• EPA Substance Registry System: 3-IMIDAZOL-1-YL-PHENYLAMINE(112677-67-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 112677-67-5(Hazardous Substances Data)

Usage

Uses

3-(1H-Imidazol-1-yl)aniline is a useful reagent for many copper-catalyzed reactions.

Upstream product

• 23309-09-3 1-(3-nitrophenyl)-1H-imidazole 
• 288-32-4 1H-imidazole 
• 591-19-5 m-Bromoaniline 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 626-01-7 3-Iodoaniline 
• 67-63-0 isopropyl alcohol 
• 30418-59-8 3-Aminophenylboronic acid 
• 585-79-5 m-nitrobromobenzene 

Downstream Products

• 333793-32-1 N-(3-(imidazol-1-yl)phenyl)-2-phenylthiazole-4-carboxamide 
• 329280-78-6 N-(5-bromo-3-nitropyridin-2-yl)-N-[3-(imidazol-1-yl)phenyl]amine 
• 374555-25-6 (3-imidazol-1ylphenyl)-(5-phenylisoquinolin-1-yl)amine 
• 374555-34-7 (5-bromoisoquinolin-1-yl)-[3-(imidazol-1-yl)phenyl]amine 
• 374555-28-9 [3-(imidazol-1-yl)phenyl]-[5-(thiophen-3-yl)isoquinolin-1-yl]amine 
• 374555-43-8 [3-(imidazol-1-yl)phenyl]-(4-phenylisoquinolin-1-yl)amine 
• 374555-44-9 [3-(imidazol-1-yl)phenyl]-[5-(4-fluorophenyl)isoquinolin-1-yl]amine 
• 374556-13-5 N-(3-(1H-imidazol-1-yl)phenyl)-9-methyl-4,5-dihydro[1]benzoxepino[5,4-c]isoxazol-3-amine 
• 374556-09-9 [3-(imidazol-1-yl)phenyl]-(7-methoxy-5,6-dihydrobenzo[h]quinazolin-2-yl)-amine 
• 112675-52-2 N-<3-(1H-imidazol-1-yl)phenyl>-4-(2-pyridinyl)-2-pyrimidinamine 
• 361552-14-9 8,9-dihydro-7H-benzocycloheptene-6-carboxylic acid(3-imidazol-1-yl-phenyl)-amide 

Relevant articles and documents

4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER

The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).

ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE

The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.

L -(-) -Quebrachitol as a Ligand for Selective Copper(0)-Catalyzed N-Arylation of Nitrogen-Containing Heterocycles

l-(-)-Quebrachitol (QCT) has been found as a ligand of copper powder for selective N-arylation of nitrogen-containing heterocycles with aryl halides. Furthermore, another potential catalytic system (copper powder/QCT/t-BuOK) was successfully adapted to unactivated aryl chlorides.

Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8

The latency-associated nuclear antigen (LANA) is required for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. It acts via replicating and tethering the virus episome to the host chromatin and exerts other functions. We conceived a new approach for the discovery of antiviral drugs to inhibit the interaction between LANA and the viral genome. We applied a biophysical screening cascade and identified the first LANA binders from small, structurally diverse compound libraries. Starting from a fragment-sized scaffold, we generated optimized hits via fragment growing using a dedicated fluorescence-polarization-based assay as the structure-activity-relationship driver. We improved compound potency to the double-digit micromolar range. Importantly, we qualified the resulting hit through orthogonal methods employing EMSA, STD-NMR, and MST methodologies. This optimized hit provides an ideal starting point for subsequent hit-to-lead campaigns providing evident target-binding, suitable ligand efficiencies, and favorable physicochemical properties.

Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8

The latency-associated nuclear antigen (LANA) is required for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. It acts via replicating and tethering the virus episome to the host chromatin and exerts other functions. We conceived a new approach for the discovery of antiviral drugs to inhibit the interaction between LANA and the viral genome. We applied a biophysical screening cascade and identified the first LANA binders from small, structurally diverse compound libraries. Starting from a fragment-sized scaffold, we generated optimized hits via fragment growing using a dedicated fluorescence-polarization-based assay as the structure-activity-relationship driver. We improved compound potency to the double-digit micromolar range. Importantly, we qualified the resulting hit through orthogonal methods employing EMSA, STD-NMR, and MST methodologies. This optimized hit provides an ideal starting point for subsequent hit-to-lead campaigns providing evident target-binding, suitable ligand efficiencies, and favorable physicochemical properties.

Efficient use of a surfactant for copper-catalyzed coupling reaction of arylboronic acids with imidazoles in water

Copper-catalyzed oxidative coupling of arylboronic acids with imidazoles in water was realized by using an amphiphilic surfactant. By choosing an appropriate surfactant, reactions of a variety of arylboronic acids proceeded smoothly under mild and base-fr

Theramutein modulators

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

Highly functional group tolerance in copper-catalyzed N-arylation of nitrogen-containing heterocycles under mild conditions

A copper-catalyzed process has been developed for the N-arylation reaction under very mild conditions in the absence of additional ligand. This protocol could not only tolerate an array of thermally sensitive functional groups, but also achieve high chemoselectivity.

Per-6-amino-β-cyclodextrin as an efficient supramolecular ligand and host for Cu(I)-catalyzed N-arylation of imidazole with aryl bromides

(Chemical Presented) Per-6-amino-β-cyclodextrin (per-6-ABCD), acting simultaneously as a supramolecular ligand for CuI and host for aryl bromides, catalyzes N-arylation of imidazole with aryl bromides under mild conditions. This simple method proceeds with excellent yield for the coupling of imidazole with various substituted aryl bromides demonstrating good tolerance of other functionalities.

THERAMUTEIN MODULATORS

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.